Pegvisomant-Induced Liver Injury Is Related to the UGT1A1*28 Polymorphism of Gilbert's Syndrome.
Conclusions: The UGT1A1*28 genotype and male gender predict an increased incidence of LFT abnormalities during PEG therapy in acromegaly.
PMID: 20207827 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 03/04/2010 at 06:00 PM --
|
Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients.
CONCLUSION: These findings accentuate the importance of recognition of the clinical manifestations of arthropathy in patients with acromegaly despite long-term disease control.
PMID: 20194043 [PubMed - as supplied by publisher] (Source: Growth Hormone and IGF Research)...
POSTED 02/26/2010 at 06:00 PM --
|
Basal, But Not Pulsatile, Growth Hormone Secretion Determines the Ambient Circulating Levels of Insulin-Like Growth Factor-I.
Conclusions: Plasma IGF-I concentrations correlated with mean 24-h GH concentrations. This relationship is dependent exclusively on the basal GH levels. GH pulses do not determine plasma IGF-I concentrations.
PMID: 20190159 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 02/25/2010 at 06:00 PM --
|
IGF-I stimulates reactive oxygen species (ROS) production and inhibits insulin-dependent glucose uptake via ROS in 3T3-L1 adipocytes.
CONCLUSIONS: These data indicate that IGF-I inhibited insulin activity in the 3T3-L1 adipocytes via ROS production, which affects IRS-1 phosphorylation status.
PMID: 20185348 [PubMed - as supplied by publisher] (Source: Growth Hormone and IGF Research)...
POSTED 02/22/2010 at 06:00 PM --
|
Calling all aspiring science writers
The Society for Endocrinology needs YOU!
The public are turning to the internet more and more in search of information on their hormones, yet how can they be sure they are getting facts not fiction?
You and Your Hormones is a new project by the Society for Endocrinology that aims to give the public online access to current, evidence-based information on the field of endocrinology. We are looking for enthusiastic and talented clinicians and scientists of any level or background to contribute articles to be published on our upcoming public website.
This is your chance to engage with and educate the public on the entire field of endocrinology, and develop your skills in science communication. Whether your expertise is in angiotensin or acromegaly, we'd really appreciate your input. In addi......
POSTED 02/11/2010 at 06:00 AM --
|
Acromegaly per se does not increase the risk for coronary artery disease.
Conclusion: CAD risk in newly diagnosed acromegalic patients was low and remained stable after successful treatment. CAC was lower than in controls suggesting that GH excess per se does not carry an additional CAD risk.
PMID: 20145047 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)...
POSTED 02/08/2010 at 06:00 PM --
|
Fractionated stereotactic radiotherapy in patients with acromegaly. Interim single centre audit.
Conclusion: The FSRT treatment seems promising in terms of treatment of acromegaly. Longer follow-up is, however, needed to assess the overall efficacy and safety of FSRT for acromegaly.
PMID: 20133445 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)...
POSTED 02/03/2010 at 06:00 PM --
|
Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population
Abstract GH and IGF-1 play an important role in the regulation of metabolism and body composition. In patients with uncontrolled acromegaly,
cardiovascular morbidity and mortality are increased but are supposed to be normalised after biochemical control is achieved.
We aimed at comparing body composition and the cardiovascular risk profile in patients with controlled acromegaly and controls.
A cross-sectional study. We evaluated anthropometric parameters (height, weight, body mass index (BMI), waist and hip circumference,
waist to height ratio) and, additionally, cardiovascular risk biomarkers (fasting plasma glucose, HbA1c, triglycerides, total
cholesterol, HDL, LDL, and lipoprotein (a), in 81 acromegalic patients (58% cured) compared to 320 age- and gender-matched
contro......
POSTED 02/03/2010 at 11:59 AM --
|
Mortality in Patients with Pituitary Disease.
Authors: Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Sheppard MC, Bates AS, Stewart PM
Pituitary disease is associated with increased mortality predominantly due to vascular disease. Control of cortisol secretion and GH hypersecretion (and cardiovascular risk factor reduction) is key in the reduction of mortality in patients with Cushing's disease and acromegaly, retrospectively. For patients with acromegaly, the role of IGF-I is less clear-cut. Confounding pituitary hormone deficiencies such as gonadotropins and particularly ACTH deficiency (with higher doses of hydrocortisone replacement) may have a detrimental effect on outcome in patients with pituitary disease. Pituitary radiotherapy is a further factor that has been associated with increased mortality (particul......
POSTED 01/18/2010 at 06:00 PM --
|
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
CONCLUSION: Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events.
PMID: 20071478 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)...
POSTED 01/12/2010 at 06:00 PM --
|
Growth Hormone Deficiency after Treatment of Acromegaly: A Randomized, Placebo-Controlled Study of Growth Hormone Replacement.
Conclusions: This is the first randomized, placebo-controlled study of the effects of GH replacement therapy on body composition and cardiovascular end points in patients who have developed GH deficiency after treatment for acromegaly, a disease complicated by metabolic and body composition alterations and increased cardiovascular risk. GH replacement decreased visceral adipose tissue, increased fat-free mass, decreased hsCRP, and improved quality of life in patients with GHD after cure of acromegaly, with minimal side effects and without an increase in insulin resistance.
PMID: 20061426 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 01/07/2010 at 06:00 PM --
|
Endocrine Aspects of Obstructive Sleep Apnea.
Conclusions: Given the potential neurocognitive consequences and increased cardiovascular risk associated with OSA, specific therapy such as continuous positive airway pressure is recommended if OSA persists despite effective treatment of its potential endocrine and metabolic causes.
PMID: 20061419 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 01/07/2010 at 06:00 PM --
|
The role of fibrinogen and CRP in cardiovascular risk in patients with acromegaly.
Conclusions: Fibrinogen plays an important role as a cardiovascular risk factor in acromegaly, irrespective of the cure of the disease. The role of CRP as a cardiovascular risk factor in patients with uncontrolled acromegaly should be better explained in future studies. (Pol J Endocrinol 2010; 61 (1): 83-88).
PMID: 20205109 [PubMed - in process] (Source: Endokrynologia Polska)...
POSTED 12/31/2009 at 06:00 PM --
|
A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
CONCLUSION: Our findings provide support for the long-term safety and efficacy of the GH receptor antagonist pegvisomant in achieving IGF-I control in patients with refractory acromegaly.
PMID: 20003832 [PubMed - in process] (Source: Clinical and Investigative Medicine)...
POSTED 12/19/2009 at 09:54 AM --
|
Development of a Disease-Specific Quality of Life Questionnaire in Addison's Disease.
Conclusions: We envisage AddiQoL having utility in trials of hormone replacement and management of patients with Addison's disease, analogous to similar questionnaires in GH deficiency (AGHDA) and acromegaly (AcroQoL).
PMID: 20016050 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 12/15/2009 at 06:00 PM --
|
The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
Abstract The Endocrine Tumor Summit convened in December 2008 to address 6 statements prepared by panel members that reflect important
questions in the treatment of acromegaly and carcinoid syndrome. Data pertinent to each of the statements were identified
through review of pertinent literature by one of the 9-member panel, enabling a critical evaluation of the statements and
the evidence supporting or refuting them. Three statements addressed the validity of serum growth hormone (GH) and insulin-like
growth factor-I (IGF-I) concentrations as indicators or predictors of disease in acromegaly. Statements regarding the effects
of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoid
syndrome, and the ef......
POSTED 12/13/2009 at 12:43 AM --
|
Hemostatic and Fibrinolytic Abnormalities in Endocrine Diseases: A Narrative Review
Semin Thromb Hemost 2009; 35: 605-612DOI: 10.1055/s-0029-1242714ABSTRACTThis review summarizes current knowledge of the effects of polycystic ovary syndrome, Cushing's syndrome, thyrotoxicosis, hypothyroidism, primary hyperparathyroidism, acromegaly, hypopituitarism, and growth hormone deficiency on coagulation and fibrinolysis. Several abnormalities of the coagulation-fibrinolytic system have been described among patients affected by these endocrine disorders. Although further larger studies are needed to provide more definitive information, clinically overt hypothyroidism appears to be associated with a bleeding tendency, whereas all other endocrine diseases appear to be associated with a thrombotic tendency. The disorders of coagulation and fibrinolysis observed in these endocrine patho......
POSTED 12/10/2009 at 08:19 AM --
|
Body size variation in insects: a macroecological perspective.
Authors: Chown SL, Gaston KJ
Body size is a key feature of organisms and varies continuously because of the effects of natural selection on the size-dependency of resource acquisition and mortality rates. This review provides a critical and synthetic overview of body size variation in insects from a predominantly macroecological (large-scale temporal and spatial) perspective. Because of the importance of understanding the proximate determinants of adult size, it commences with a brief summary of the physiological mechanisms underlying adult body size and its variation, based mostly on findings for the model species Drosophila melanogaster and Manduca sexta. Variation in nutrition and temperature have variable effects on critical weight, the interval to cessation of growth (or terminal ......
POSTED 12/09/2009 at 06:00 PM --
|
Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study.
Conclusions: This study shows that pegvisomant therapy infrequently coincides with tumor growth during long-term treatment of acromegaly. Because all significant tumor volume increases occurred during the first year, these changes might correlate to the change of medication and thus be the result of a rebound from somatostatin-induced shrinkage.
PMID: 19965922 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)...
POSTED 12/03/2009 at 06:00 PM --
|
Low ACTH, High Steroid Doses Tied to Acromegaly Mortality
In patients with acromegaly, deficiency in adrenocorticotropic hormone (ACTH) and radiotherapy are among the factors associated with increased mortality, UK researchers report in the November issue of the Journal of Clinical Endocrinology and Metabolism. Reuters Health Information (Source: Medscape Today Headlines)...
POSTED 12/01/2009 at 11:48 AM --
|
